10-Q: Intelligent Bio Solutions Reports Q2 2025 Results, Highlights FDA Submission and Strategic Partnerships

Intelligent Bio Solutions Inc. announces its financial results for the quarter ended December 31, 2024, alongside key operational achievements including the FDA 510(k) submission and new strategic partnerships.

Summary

• Intelligent Bio Solutions Inc. reported a net loss of $2.25 million for the three months ended December 31, 2024, compared to a net loss of $1.98 million for the same period in 2023.
• Revenue decreased to $607,494 from $764,063 year-over-year, primarily due to instability in the construction sector impacting reader sales.
• Gross profit increased to $223,113 from $199,248 year-over-year, driven by a higher proportion of high-margin cartridge sales and enhanced production efficiency.
• The company submitted its 510(k) premarket notification to the US FDA for its Intelligent Fingerprinting Drug Screening System on December 18, 2024.
• Operating expenses totaled $2.62 million, compared to $2.34 million in the prior year, with increased development and regulatory approval expenses.
• The company raised approximately $676,619 through the sale of 438,367 shares of common stock under the ATM agreement during the quarter.
• As of December 31, 2024, the company's cash and cash equivalents were $2.24 million, and the company has a working capital deficit of $341,243.
• The company anticipates needing to raise additional funds within the next 12 months to fund its operating plan.
• The company has identified material weaknesses in its internal control over financial reporting.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the increased net loss, decreased revenue, working capital deficit, the need for additional funding, and the identified material weaknesses in internal control over financial reporting. However, the FDA submission and strategic partnerships provide some positive offset.

Positives

• Gross profit margin improved due to a strategic sales mix favoring high-margin cartridge sales and enhanced production efficiency.
• The company successfully submitted its 510(k) premarket notification to the US FDA.
• The company secured 19 new accounts during the quarter, expanding its customer base.
• The company completed a method comparison clinical study confirming the sensitivity, specificity, accuracy, and usability of its Intelligent Fingerprinting Drug Screening System.
• The company announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign.
• The company announced a distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency.

Negatives

• Revenue decreased by $156,569 to $607,494 for the three months ended December 31, 2024, compared to the same period in 2023.
• Net loss increased by $279,829 to $2,249,470 for the three months ended December 31, 2024, compared to the same period in 2023.
• The company has a working capital deficit of $341,243 as of December 31, 2024.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company anticipates needing to raise additional funds within the next 12 months to fund its operating plan, and there is no assurance that such financing will be available on favorable terms or at all.
• Failure to generate sufficient revenues or raise additional capital could have a material adverse effect on the company's ability to meet its long-term liquidity needs and achieve its intended long-term business plan.
• The company has only completed 4 of the 8 agreed-upon milestones set forth in the company's grant agreement with the Australian government related to the construction of a manufacturing facility in Australia, and will be required to refund certain amounts from the grant.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company anticipates operating losses for the foreseeable future and expects that its cash and cash equivalents as of December 31, 2024, may be insufficient to allow the company to fund its current operating plan through at least the next twelve months. The company will be required to raise additional funds during the next 12 months.

Management Comments

• Management believes there is a material risk that the Company's cash and cash equivalents as of December 31, 2024, of approximately $ 2.24 million, will be insufficient to fund its current operating plan through at least the next twelve months from the issuance of these unaudited condensed consolidated financial statements.
• Management is committed to continuing the steps necessary to remediate the control deficiencies that constituted the above material weaknesses.

Industry Context

The company operates in the medical technology industry, specifically focusing on drug screening solutions. The submission of the 510(k) to the FDA is a critical step for entering the US market, which is a significant opportunity for growth. Strategic partnerships with marketing and consulting agencies are aimed at increasing market awareness and expanding the company's reach.

Comparison to Industry Standards

• It's difficult to provide a precise comparison to industry standards without knowing the specific peer group Intelligent Bio Solutions considers its direct competitors.
• However, companies like Abbott, Roche, and Siemens Healthcare offer a broad range of diagnostic products, including drug screening solutions, and serve as benchmarks for market presence and regulatory compliance.
• Smaller, more focused companies like OraSure Technologies or Chembio Diagnostics might be more relevant comparables in terms of market capitalization and product focus, but their financial performance and growth trajectories would need to be analyzed in detail to draw meaningful comparisons.
• The success of Intelligent Bio Solutions will depend on its ability to secure FDA approval, effectively commercialize its products, and compete with established players in the drug screening market.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures if additional funding is not secured.
• Customers may benefit from the potential FDA approval and wider availability of the company's drug screening system.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will continue to pursue FDA clearance for its Intelligent Fingerprinting Drug Screening System.
• The company will continue to execute its strategic partnerships to expand market reach.
• The company will need to secure additional funding to support its operations.
• The company will continue to remediate the identified material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

Intelligent Bio Solutions, Drug Screening, FDA 510(k), Financial Results, Partnerships, Revenue, Net Loss, ATM Offering, Internal Controls, Liquidity